Walleye Capital LLC Buys Shares of 125,232 Zenas BioPharma, Inc. $ZBIO

Walleye Capital LLC purchased a new stake in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 125,232 shares of the company’s stock, valued at approximately $2,448,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBIO. SEB Asset Management AB purchased a new stake in Zenas BioPharma in the 1st quarter worth about $3,203,000. Jennison Associates LLC bought a new stake in Zenas BioPharma in the 1st quarter valued at about $4,888,000. Bank of New York Mellon Corp lifted its holdings in Zenas BioPharma by 17.5% during the first quarter. Bank of New York Mellon Corp now owns 60,864 shares of the company’s stock valued at $1,190,000 after purchasing an additional 9,062 shares during the last quarter. iA Global Asset Management Inc. purchased a new stake in Zenas BioPharma during the first quarter valued at about $4,219,000. Finally, Invesco Ltd. boosted its position in Zenas BioPharma by 28.9% during the fourth quarter. Invesco Ltd. now owns 187,968 shares of the company’s stock worth $6,825,000 after purchasing an additional 42,172 shares during the period.

Insider Activity

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. acquired 60,000 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were bought at an average price of $16.88 per share, for a total transaction of $1,012,800.00. Following the completion of the transaction, the chief executive officer owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. This represents a 162.48% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired a total of 120,000 shares of company stock valued at $2,080,000 in the last quarter. Company insiders own 22.00% of the company’s stock.

Zenas BioPharma Stock Down 1.6%

ZBIO stock opened at $30.99 on Friday. The stock has a 50-day simple moving average of $22.73 and a two-hundred day simple moving average of $22.01. Zenas BioPharma, Inc. has a twelve month low of $13.50 and a twelve month high of $44.60. The firm has a market capitalization of $1.96 billion, a PE ratio of -3.66 and a beta of -0.96. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same quarter in the prior year, the company earned ($0.80) earnings per share. On average, equities analysts predict that Zenas BioPharma, Inc. will post -4.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Citigroup reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, Morgan Stanley boosted their target price on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.29.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.